Sirio Pharma (300791) - Net Assets
Based on the latest financial reports, Sirio Pharma (300791) has net assets worth CN¥2.66 Billion CNY (≈ $389.79 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.74 Billion ≈ $839.26 Million USD) and total liabilities (CN¥3.07 Billion ≈ $449.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Sirio Pharma (300791) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.66 Billion |
| % of Total Assets | 46.44% |
| Annual Growth Rate | 24.25% |
| 5-Year Change | 21.01% |
| 10-Year Change | N/A |
| Growth Volatility | 46.12 |
Sirio Pharma - Net Assets Trend (2016–2024)
This chart illustrates how Sirio Pharma's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Sirio Pharma worth.
Annual Net Assets for Sirio Pharma (2016–2024)
The table below shows the annual net assets of Sirio Pharma from 2016 to 2024. Also explore Sirio Pharma annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.64 Billion ≈ $386.49 Million |
+2.92% |
| 2023-12-31 | CN¥2.57 Billion ≈ $375.51 Million |
-5.01% |
| 2022-12-31 | CN¥2.70 Billion ≈ $395.32 Million |
+6.16% |
| 2021-12-31 | CN¥2.54 Billion ≈ $372.38 Million |
+16.59% |
| 2020-12-31 | CN¥2.18 Billion ≈ $319.40 Million |
+12.22% |
| 2019-12-31 | CN¥1.95 Billion ≈ $284.62 Million |
+148.08% |
| 2018-12-31 | CN¥784.05 Million ≈ $114.73 Million |
+35.13% |
| 2017-12-31 | CN¥580.20 Million ≈ $84.90 Million |
+24.78% |
| 2016-12-31 | CN¥464.98 Million ≈ $68.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sirio Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 459.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.52 Billion | 60.46% |
| Other Components | CN¥990.77 Million | 39.54% |
| Total Equity | CN¥2.51 Billion | 100.00% |
Sirio Pharma Competitors by Market Cap
The table below lists competitors of Sirio Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong Vanward New Electric Co Ltd
SHE:002543
|
$778.01 Million |
|
Shandong New Beiyang Information Technology Co Ltd
SHE:002376
|
$778.09 Million |
|
Hangzhou Huaguang Advanced Welding Materials Co Ltd
SHG:688379
|
$778.31 Million |
|
Gujarat Ambuja Exports Limited
NSE:GAEL
|
$778.53 Million |
|
South Plains Financial Inc
NASDAQ:SPFI
|
$777.89 Million |
|
SERVICE STREAM LTD
F:UFY
|
$777.83 Million |
|
Guangdong SACA Precision Manufacturing Co Ltd
SHE:300464
|
$777.79 Million |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
$777.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sirio Pharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,390,032,229 to 2,505,833,682, a change of 115,801,453 (4.8%).
- Net income of 325,061,747 contributed positively to equity growth.
- Dividend payments of 219,627,551 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥325.06 Million | +12.97% |
| Dividends Paid | CN¥219.63 Million | -8.76% |
| Other Changes | CN¥10.37 Million | +0.41% |
| Total Change | CN¥- | 4.85% |
Book Value vs Market Value Analysis
This analysis compares Sirio Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.03x to 1.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥4.30 | CN¥17.30 | x |
| 2018-12-31 | CN¥5.81 | CN¥17.30 | x |
| 2019-12-31 | CN¥10.81 | CN¥17.30 | x |
| 2020-12-31 | CN¥12.13 | CN¥17.30 | x |
| 2021-12-31 | CN¥14.12 | CN¥17.30 | x |
| 2022-12-31 | CN¥14.97 | CN¥17.30 | x |
| 2023-12-31 | CN¥7.79 | CN¥17.30 | x |
| 2024-12-31 | CN¥10.62 | CN¥17.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sirio Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.97%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.72%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 2.19x
- Recent ROE (12.97%) is below the historical average (28.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 151.35% | 89.51% | 0.54x | 3.14x | CN¥657.23 Million |
| 2017 | 17.98% | 7.84% | 1.03x | 2.22x | CN¥46.28 Million |
| 2018 | 25.92% | 12.74% | 1.03x | 1.97x | CN¥124.82 Million |
| 2019 | 7.33% | 9.02% | 0.67x | 1.21x | CN¥-51.98 Million |
| 2020 | 11.79% | 12.45% | 0.78x | 1.21x | CN¥39.10 Million |
| 2021 | 9.11% | 9.79% | 0.62x | 1.50x | CN¥-22.64 Million |
| 2022 | 7.86% | 8.47% | 0.60x | 1.55x | CN¥-57.87 Million |
| 2023 | 11.76% | 7.85% | 0.69x | 2.17x | CN¥42.04 Million |
| 2024 | 12.97% | 7.72% | 0.77x | 2.19x | CN¥74.48 Million |
Industry Comparison
This section compares Sirio Pharma's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $1,405,352,646
- Average return on equity (ROE) among peers: 0.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sirio Pharma (300791) | CN¥2.66 Billion | 151.35% | 1.15x | $777.99 Million |
| Shenzhen Shenbao Industrial Co Ltd (000019) | $993.64 Million | 1.34% | 0.16x | $1.15 Billion |
| Hainan Pearl River Holdings Co Ltd (000505) | $770.02 Million | 0.67% | 0.70x | $649.98 Million |
| Xiwang Foodstuffs Co Ltd (000639) | $4.10 Billion | -18.34% | 0.99x | $255.89 Million |
| Nanfang Black Sesame Group Co Ltd (000716) | $2.65 Billion | 1.62% | 0.68x | $558.56 Million |
| CNFC Overseas Fishery Co Ltd (000798) | $811.32 Million | 0.67% | 0.20x | $543.40 Million |
| Henan Shuanghui Investment & Development Co Ltd (000895) | $761.85 Million | 7.40% | 0.52x | $11.81 Billion |
| Xinjiang Chalkis Co Ltd (000972) | $447.94 Million | 1.11% | 0.65x | $440.17 Million |
| Zhengzhou Qianweiyangchu Food Co Ltd (001215) | $274.27 Million | 16.98% | 0.48x | $432.93 Million |
| Qingdao Foods Co Ltd (001219) | $465.66 Million | 16.99% | 0.17x | $355.80 Million |
| Shandong Oriental Ocean Sci-Tech Co Ltd (002086) | $2.78 Billion | -28.38% | 0.50x | $576.18 Million |
About Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. … Read more